Canaccord analyst Richard Close noted Clover Health announced a partnership with UST HealthProof. Through the partnership, Clover will move its core plan operations to UST HealthProof’s integrated technology platform, allowing Clover to focus on its core competencies providing broad network, benefitrich health plans with differentiated capabilities through Clover Home Care and its physician enablement technology, Clover Assistant. We are encouraged by Clover being proactive in reducing the timeline to profitability and look to gain additional insight from the company when it reports 1Q results. Canaccord maintains its Buy rating and $3 price target on Clover Health shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLOV:
- Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability
- Clover Health announces transformation initiatives, eliminates 10% of staff
- Clover Health to Report First Quarter 2023 Financial Results on May 9, 2023
- TD Cowen healthcare analyst to hold analyst/industry conference call
- Clover Health to Present at Barclays 2023 Global Healthcare Conference on March 14, 2023
